![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/27/2905530/0/en/Acasti-Announces-Achievement-of-50-Enrollment-in-Pivotal-Phase-3-STRIVE-ON-Safety-Trial.html
https://www.globenewswire.com/news-release/2024/06/21/2902257/0/en/Acasti-Announces-Year-End-2024-Financial-Results-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/05/28/2889416/0/en/Acasti-Pharma-to-Attend-BIO-International-Convention-2024.html
https://www.globenewswire.com//news-release/2024/02/12/2827471/0/en/Acasti-Announces-Third-Fiscal-Quarter-2024-Financial-Results-and-Business-Highlights.html
https://www.globenewswire.com//news-release/2024/02/01/2821916/0/en/Acasti-Announces-Poster-Detailing-its-GTX-104-STRIVE-ON-Trial.html
https://www.globenewswire.com//news-release/2023/12/13/2795501/0/en/Acasti-to-Participate-in-Upcoming-San-Francisco-Investor-Conferences-in-January-2024.html
https://www.globenewswire.com//news-release/2023/11/13/2779016/0/en/Acasti-Announces-Second-Quarter-2024-Financial-Results-and-Business-Highlights.html
https://www.globenewswire.com//news-release/2023/10/23/2764681/0/en/Acasti-Announces-Dosing-of-First-Patient-in-GTX-104-STRIVE-ON-Trial.html
https://www.globenewswire.com//news-release/2023/10/04/2754500/0/en/Acasti-Pharma-to-Host-KOL-Event-on-GTX-104-A-Potential-New-Treatment-Standard-for-Rare-and-Life-Threatening-aneurysmal-Subarachnoid-Hemorrhage-aSAH.html
https://www.globenewswire.com//news-release/2023/09/26/2749418/0/en/Acasti-Announces-7-5-Million-Private-Placement-Equity-Financing.html